Vogenx (VOGX)
Develops an oral SGLT1 inhibitor for post-bariatric hypoglycemia.
$26.55
vs last close−0.02 (−0.08%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Strategic holders | 13.83% | 1.92M shares | |
|---|---|---|---|
| 1 holder · as of Sep 8, 2026 | |||
| Other | 86.17% | 11.98M shares | |
| remainder | |||
13.91M company shares as of Sep 3, 2026 · holders as of their latest filing
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 13.00% | 1.92M | 13G | Sep 8, 2026 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.